Peptides DB
Research-centric peptide and protocol reference hub
Study 45 of 48Vasopressin literaturebiorxiv-preprint · Observational2026

AVPR2 antagonism with tolvaptan alters medullary cell responses and attenuates kidney injury

Tolvaptan may reduce kidney injury-related inflammation and stress responses in a mouse model, but its clinical relevance in humans is unclear.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the vasopressin corpus
9
Preclinical
35
Observational · this one
1
Open-label
2
Randomised
1
Reviews

Summary and findings

This study examined the effects of the AVPR2 antagonist Tolvaptan on kidney responses in male mice following ischemia-reperfusion injury and cisplatin administration. It reported that Tolvaptan reduced urine and medullary tissue osmolality and altered gene expression related to stress and inflammation. The findings suggest potential benefits of AVPR2 antagonism in kidney injury contexts.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<h4>ABSTRACT</h4> <h4>Introduction</h4> Arginine vasopressin receptor 2 (AVPR2) signaling regulates kidney collecting duct signaling and urinary concentration, but the kidney’s cell-type-specific responses to its pharmacological inhibition and their relevance to non-cystic kidney injury remain incompletely characterized. <h4>Methods</h4> We examined physiological and transcriptional responses to the AVPR2 antagonist Tolvaptan in uninjured male mice and assessed tissue outcomes after unilateral ischemia-reperfusion injury (IRI) and repeated cisplatin administration. Analyses included renal tissue osmolality measurements, single nucleus and bulk RNA sequencing of kidney tissues, quantitative PCR, in situ hybridization, and histology. <h4>Results</h4> In uninjured kidneys, Tolvaptan reduced urine and medullary tissue osmolality and altered transcription predominantly in medullary collecting-duct populations, including lower expression of selected stress-associated and proinflammatory genes. Following IRI, Tolvaptan-treated mice exhibited attenuated expression of inflammatory and monocyte recruitment genes, reduced macrophage accumulation in the renal medulla, and diminished fibrotic remodeling. In cisplatin-induced kidney injury Tolvaptan reduced tubular injury markers and inflammatory activation in the outer medulla. <h4>Conclusions</h4> Tolvaptan attenuates medullary tubular stress responses and post-injury inflammation and fibrosis. These findings extend the effects of pharmacological AVPR2 antagonism beyond water homeostasis to tissue-level responses in non-cystic kidney injury. <h4>TRANSLATIONAL STATEMENT</h4> Acute kidney injury can lead to persistent inflammation and fibrotic remodeling, yet the contribution of medullary Avpr2 signaling to these processes remains poorly understood. In mice, treatment with the clinically used Avpr2 antagonist Tolvaptan reduced medullary osmolality and modulated stress-associated tubular transcriptomes. Tolvaptan treatment initiated before injury reduced selected inflammatory and tissue remodeling endpoints in experimental kidney injury. These findings support further investigation of pharmacological AVPR2 antagonism in non-cystic kidney disease.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Vasopressin corpus

BRefractory circulatory shock following intentional polypharmacy antihypertensive and NSAID overdose: Clinical recovery temporally associated with sequential intravenous lipid emulsion and methylene blue - A case report.Toxicology reports · 2026 · n=1 · Lactate fell from 10.5 to 6.1 mmol/L over 55 min.HumanCAllelic heterogeneity and cystic pathway modulation in HNF1B diseasebiorxiv-preprint · 2026 · Not reported in abstract.AnimalBCost Analysis of Vasopressin Use in Septic Shock and Predictive Performance of GOSSIS in ICU Mortalitybiorxiv-preprint · 2026 · cost ratio = 1.14, 95% CI: 1.08, 1.20HumanBFluid Resuscitation Volume After Early Echocardiography and Mortality in Sepsis: Target Trial Emulations With Strictly Pre-Exposure Confounder Measurement in MIMIC-IVbiorxiv-preprint · 2023 · n=7819 · HR 1.74, 95% CI 1.54–1.97; weighted risk 38.7% vs 24.8%; risk difference +13.9%, 95% CI 10.8–17.0.HumanBAcute colonic pseudo-obstruction with transient failure of oral desmopressin in adipsic arginine vasopressin deficiency.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanAEffect of Vasopressin Initiation Threshold on Septic Shock Mortality: The VASSPR Cluster Crossover Randomized Strategy Trial.JAMA · 2026 · Mortality at 28 days was 31.8% in the lower-threshold group vs 33.0% in the higher-threshold group, P=0.62.Human